Lead Product Candidate LB1148

LB1148

Lead Product Candidate LB1148

Our lead program, LB1148, is a broad-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, potentially reducing intestinal damage. In multiple clinical studies, LB1148 has demonstrated positive results in accelerating the time to return of postoperative bowel function and preventing the post-surgical formation of abdominal adhesions. LB1148 is currently being evaluated in a Phase 3 clinical study for accelerating the return of postoperative bowel function and in a Phase 2 study for the prevention of post-surgical abdominal adhesions.

LB1148 Highlights

LB1148: Granted FDA Fast Track Designation for Two Indications
  • Reduction of the formation of intra-abdominal adhesions following abdominal or pelvic surgery; and
  • Treatment of postoperative GI dysfunction (which may present as feeding intolerance, ileus, necrotizing enterocolitis, etc.) associated with gut hypoperfusion injury in pediatric patients who underwent congenital heart disease repair surgery.
 
Post Operative Bowel Function is a Big Bottleneck
  • Patients generally do not leave the hospital until having a bowel movement
  • Delayed bowel movement causes prolonged hospital stays and increased costs
Abdominal Adhesions are a Significant Medical Burden